ATE354802T1 - Methoden zum screening knochenmorphogenetishemimetika - Google Patents

Methoden zum screening knochenmorphogenetishemimetika

Info

Publication number
ATE354802T1
ATE354802T1 AT00992674T AT00992674T ATE354802T1 AT E354802 T1 ATE354802 T1 AT E354802T1 AT 00992674 T AT00992674 T AT 00992674T AT 00992674 T AT00992674 T AT 00992674T AT E354802 T1 ATE354802 T1 AT E354802T1
Authority
AT
Austria
Prior art keywords
methods
agents
morphogenetishemimetics
screening bone
daf
Prior art date
Application number
AT00992674T
Other languages
English (en)
Inventor
Dattatreymurty Bosukonda
Original Assignee
Thrasos Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thrasos Inc filed Critical Thrasos Inc
Application granted granted Critical
Publication of ATE354802T1 publication Critical patent/ATE354802T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Reproductive Health (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
AT00992674T 2000-11-06 2000-12-07 Methoden zum screening knochenmorphogenetishemimetika ATE354802T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24623100P 2000-11-06 2000-11-06

Publications (1)

Publication Number Publication Date
ATE354802T1 true ATE354802T1 (de) 2007-03-15

Family

ID=22929832

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00992674T ATE354802T1 (de) 2000-11-06 2000-12-07 Methoden zum screening knochenmorphogenetishemimetika

Country Status (8)

Country Link
US (3) US20040009532A1 (de)
EP (1) EP1334365B1 (de)
AT (1) ATE354802T1 (de)
AU (1) AU2001245209A1 (de)
CA (1) CA2431552A1 (de)
DE (1) DE60033576T2 (de)
ES (1) ES2282163T3 (de)
WO (1) WO2002039118A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69737809T2 (de) * 1996-01-22 2008-02-21 Curis, Inc., Cambridge Methoden zur herstellung von op-1 morphogen analoge
US20030185792A1 (en) * 1996-01-22 2003-10-02 Curis, Inc. Morphogen analogs of bone morphogenic proteins
AU2003215280A1 (en) 2002-02-15 2003-09-09 Northwestern University Self-assembly of peptide-amphiphile nanofibers under physiological conditions
EP1572950B1 (de) * 2002-06-17 2012-10-10 Thrasos, Inc. Einzeldomäne-tdf-verwandte verbindungen und analoge davon
US7554021B2 (en) 2002-11-12 2009-06-30 Northwestern University Composition and method for self-assembly and mineralization of peptide amphiphiles
EP2441474B1 (de) 2003-10-17 2015-08-05 Joslin Diabetes Center, Inc. Verfahren und Zusammensetzungen zur Modulation der Adipozytfunktion
CN102225964A (zh) 2003-12-05 2011-10-26 西北大学 自组装的肽两亲物和用于生长因子传递的相关方法
EP2319526A1 (de) 2004-06-17 2011-05-11 Thrasos Therapeutics, Inc. TDF-ähnliche Verbindungen und deren Analogal
EP1847265A4 (de) * 2005-01-26 2008-04-30 Mian Long Verwendung on flavonol und flavonolglykosiden zur stimulierung des wachstums renal-tubulärer epithelzellen zur sezernierung des nierensezernierenden knochenwachstumsfaktors
US20100150885A1 (en) 2005-06-01 2010-06-17 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis
HUE026634T2 (en) 2005-09-20 2016-07-28 Thrasos Innovation Inc TDF-related compounds and analogues thereof
US8076295B2 (en) 2007-04-17 2011-12-13 Nanotope, Inc. Peptide amphiphiles having improved solubility and methods of using same
CA2700831A1 (en) * 2007-09-28 2009-04-09 Stryker Corporation Methods for detecting neutralizing antibodies for bone morphogenetic proteins
AU2010236584A1 (en) 2009-04-13 2011-11-10 Northwestern University Novel peptide-based scaffolds for cartilage regeneration and methods for their use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567584A (en) * 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US5650276A (en) * 1991-03-11 1997-07-22 Creative Biomolecules, Inc. Morphogenic protein screening method
US6071695A (en) * 1992-02-21 2000-06-06 Creative Biomolecules, Inc. Methods and products for identification of modulators of osteogenic protein-1 gene expression
US6248554B1 (en) * 1993-11-24 2001-06-19 The Procter & Gamble Company DNA sequence coding for a BMP receptor
CA2187902A1 (en) * 1994-04-29 1995-11-09 Peter Ten Dijke Morphogenic protein-specific cell surface receptors and uses therefor
US5981483A (en) * 1994-05-04 1999-11-09 Mount Sinai Hospital Corporation Compositions comprising modulators of cytokines of the TGF-β superfamily
US6083690A (en) * 1995-06-02 2000-07-04 Osteoscreen, Inc. Methods and compositions for identifying osteogenic agents
US6190659B1 (en) * 1996-09-17 2001-02-20 The Rockefeller University Bacterial plasmin binding protein and methods of use thereof
JP2003527076A (ja) * 1999-04-09 2003-09-16 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 骨形態形成タンパク質

Also Published As

Publication number Publication date
WO2002039118A1 (en) 2002-05-16
US20090124537A1 (en) 2009-05-14
EP1334365A1 (de) 2003-08-13
ES2282163T3 (es) 2007-10-16
WO2002039118A8 (en) 2002-12-27
US20110081662A1 (en) 2011-04-07
EP1334365B1 (de) 2007-02-21
US20040009532A1 (en) 2004-01-15
DE60033576D1 (de) 2007-04-05
DE60033576T2 (de) 2007-10-31
CA2431552A1 (en) 2002-05-16
AU2001245209A1 (en) 2002-05-21

Similar Documents

Publication Publication Date Title
ATE380187T1 (de) Agonisten und antagonisten für den lpa-rezeptor und anwendungsmethoden
TR200100267T2 (tr) İkameli anilid bileşimleri ve yöntemler.
ATE354802T1 (de) Methoden zum screening knochenmorphogenetishemimetika
NO20042964L (no) Spiroazasykliske forbindelser som monoaminreseptormodulatorer
AR038563A1 (es) Composicion de ziprasidona y controles sinteticos
NO983431D0 (no) Anti-kl°emidler
EP1017713A4 (de) ZYKLISCHE AGONISTEN UND ANTAGONISTEN DER C5a REZEPTOREN SOWIE G-PROTEIN GEKOPPELTEN REZEPTOREN
ATE322258T1 (de) Methoden und zusammensetzungen zur modulation der aktivität der alpha-adrenergen rezeptoren
ATE288747T1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
AU5301201A (en) Methods of modulating hair growth
DE60217147D1 (de) Lactamderivaten zur verwendung als humane 11cby rezeptorantagonisten
TW200607814A (en) Cell surface receptor isoforms and methods of identifying and using the same
WO2003068944A3 (en) METHODS AND COMPOSITION FOR MODULATING TYPE I MUSCLE FORMATION USING PGC-1α-
EA200600440A1 (ru) 4-((феноксиалкил)тио)еноксиуксусные кислоты и их аналоги
ATE309543T1 (de) Natürlicher ligand von gpcr chemr23 und dessen verwendung
WO2005117968A3 (en) Compositions and methods comprising an egfl7 antagonist for modulating vascular development
DE69935670D1 (de) Behandlung von dyskinesie durch mu-selektive opioidantagonisten
YU17503A (sh) Receptor oblasti (ii) edb-fibronektina
DE59809283D1 (de) Inhibitoren für den urokinaserezeptor
ATE269085T1 (de) Verwendung von diltiazem zur behandlung von pathologien der netzhaut
EA200700951A1 (ru) БЕЛКИ, СОДЕРЖАЩИЕ ДОМЕНЫ vWFA И/ИЛИ ANT_IG
DK0900218T3 (da) Heterocykliske forbindelser
ATE545866T1 (de) Liganden von g-protein-gekoppelten rezeptoren und verfahren
CY1110278T1 (el) Μεθοδος διαλογης παραγοντων ικανων να θεραπευουν την παχυσαρκια
GB0213698D0 (en) Receptor

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1334365

Country of ref document: EP

REN Ceased due to non-payment of the annual fee